amyloid precursor-like protein 2; ectodomain shedding; epidermal growth factor; protein kinase C; mitogen-activated protein kinase THE MAMMALIAN AMYLOID PRECURSOR FAMILY is composed of three highly conserved transmembrane glycoproteins, the amyloid precursor protein (APP) and amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2) (29, 73, 74) . APP is the precursor of A␤ peptides of 39-43 amino acids, which are the major component of cerebrovascular and neuritic plaques or amyloid deposits found in the brains of patients with Alzheimer's disease (18, 51) . Like APP, APLP2 is encoded by alternatively spliced mRNAs. One of the spliced exons has structural/functional homology to the Kunitz-type serine protease inhibitors (KPI) (66, 74) , and one controls the addition of chondroitin sulfate (CS) to the core protein (54, 68, 69) . Both APP and APLP2 are ubiquitously expressed in mammalian tissues and cells, and a variety of physiological and pathological roles have been suggested for these two proteins (3, 10, 13, 25, 46, 51, 52) .
The APP family proteins are members of a large, functionally and structurally heterogeneous group of transmembrane proteins that undergo proteolytic cleavage and release their ectodomains into the extracellular milieu (termed ectodomain shedding or secretion) (34, 49, 55) . Ectodomain shedding has attracted much attention recently because the proteins concerned are involved in pathophysiological processes such as neurodegeneration, apoptosis, oncogenesis, and inflammation (26) . These shed proteins include receptors for tumor necrosis factor-␣ (TNF-␣) and interleukin-6; growth factors/cytokines such as TNF-␣, transforming growth factor-␣ (TGF-␣), epidermal growth factor (EGF), and heparin-binding EGF (HB-EGF); and cell adhesion molecules such as vascular cell adhesion molecule, E-and L-selectin, and syndecan-1 and -4, for example (26, 65) . Members of the APP family may share significant overlap in function and expression. Although their functions are unknown, members of the APP protein family have features in common with cell adhesion molecules and CS proteoglycans, important constituents of the cell surface and the extracellular matrix (ECM) of mammalian cells (13, 49) . Thus the release of ectodomains of APP and APLP2 and their incorporation into ECM proteins would change the properties of ECM and microenvironments. Consistent with this, we observed APLP2 accumulation at the wound bed in front of the leading edge of migratory epithelium (22) . Hence, shedding of APLP2 in corneal epithelial cells may be an important regulatory step for APLP2 to function in modulation of corneal epithelial migration and wound healing.
Shedding is believed to be under stringent regulation in vivo. One of the best studied proteins for ectodomain shedding is APP. APP can be processed by ␣-secretase to generate a large secreted form and nonamyloidogenic carboxy-terminal fragments or by a ␤-secretase to generate A␤ (reviewed in Ref. 51 ). Processing of APP by ␣-secretase is known as ectodomain shedding and precludes A␤ formation (14, 56) . This process is known to be regulated by a growing list of neurotransmitters, growth factors, cytokines, and hormones (reviewed in Ref. 38) . In response to these stimuli, several intracellular cascades have been implicated in the regulation of APP processing. Phorbol esters that directly activate most protein kinase C (PKC) isozymes are often used experimentally to induce shedding; numerous studies have shown that activation of PKC by phorbol 12-myristate 13-acetate (PMA) enhances APP cleavage in a variety of cell lines as well as in primary neuronal cultures (33, 36, 37, 40, 57) . Neurotransmitters and neuropeptides have been shown to stimulate G proteincoupled receptors and regulate APP processing by PKC-dependent signaling pathways (38, 42, 43) .
PKC is composed of a family of closely related serine/ threonine protein kinases consisting of at least 12 isozymes (39) . The role of various PKC isozymes in regulating APP processing has not been addressed extensively (38) . PKC isozymes may directly activate a specific function of cells or trigger a cascade of protein kinases that ultimately stimulates a specific cellular response (39). Izumi et al. (27) showed that upon PMA stimulation, PKC-␦ phosphorylates ADAM-9, a member of a disintegrin and metalloproteinase (ADAM) family, resulting in cleavage of the membrane-anchored form and release of the soluble form of HB-EGF. PKC-␣ and -⑀, but not PKC-␦, have been implicated in regulation of APP shedding in fibroblast cell lines (28, 60) . The underlying mechanisms used by these isozymes to activate this process are not clear.
In addition to activation of PKC, several other intracellular signaling pathways have been implicated to act as intermediaries in PKC-independent neurotransmitter receptor regulation of APP processing, including the second messengers Ca 2ϩ , phospholipase A 2 , and cAMP-dependent protein kinase (7, 40-42, 45, 59) . Furthermore, growth factors, including nerve growth factor (NGF) (12) , EGF (58) , and insulin (62) , have been found to stimulate APP processing through tyrosine kinase receptors in a PKC-independent manner (reviewed in Ref. 38) . Recent studies have suggested that the mitogen-activated protein kinase (MAPK) signaling cascade acts as an effector pathway for activating shedding metalloproteinase(s) and consequent ectodomain release (12, (15) (16) (17) 36) . Thus it is interesting to determine whether PKC functions via activation of MAPK signaling pathways in mediating ectodomain shedding.
Unlike APP, the processing of APLP2 and its regulation have not been extensively studied. APLP2 is suggested to be processed similarly to APP, since such ectodomain shedding of APLP2 may influence the amyloidogenic process of APP (35) . However, the sequences in the region in which the cleavage site for ␣-secretase resides, ϳ100 amino acids amino-terminal to the putative membrane-spanning segment, are divergent between APP and APLP2 (48, 63, 72, 74) . Recently, two widely different functions have been ascribed to APLP2 but not to other members of the APP family. They play a role in chromosome replication and/or segregation (46, 72) and in association with the major histocompatibility complex class I molecule K d (53) . At least in the latter case, the unique function of APLP2 is related to the processing of the protein. Our observation that APLP2, but not APP, is upregulated in healing corneal epithelial cells and that secreted APLP2 is accumulated on the wound bed in front of the migratory epithelial sheet suggests that ectodomain shedding of APLP2 may be involved in modulating corneal epithelial wound healing (22) . Thus differences in amino acid sequences and in functions of these two closely related proteins would imply subtle differences in regulation of APLP2 shedding from that of APP. It is, therefore, of interest to understand regulation of APLP2 processing.
Recently, we identified multiple PKC isozymes expressed in human corneal epithelial cells and found that EGF stimulation failed to induce PKC isozyme translocation (Xu, Dartt, and Yu, unpublished observations). The aim of the current study was to begin to understand the signaling mechanisms that result in the activation of ectodomain shedding of APLP2. We have provided evidence that PKC-and EGF-induced, as well as basal, APLP2 shedding is modulated by the MAPK pathway. We have also shown that PKC-⑀ isozyme might be involved in PMA-induced APLP2 shedding.
MATERIALS AND METHODS

Materials.
PMA from Sigma (St. Louis, MO) was dissolved in dimethyl sulfoxide and kept at Ϫ20°C. Stocks were diluted in culture medium before experiments. Control media always contained equivalent concentrations of the solvent. EGF was purchased from R&D Systems (Minneapolis, MN). Staurosporine and U-0126 were from Calbiochem (San Diego, CA). Fluorescein isothiocyanate (FITC)-streptavidin was from Jackson ImmunoLab (West Grove, PA), rhodamine-phalloidin was from Molecular Probes (Eugene, OR), and Vectashield mounting medium with 4Ј,6-diamidino-2-phenylindole (DAPI) was from Vector Lab (Burlingame, CA). All other chemicals were purchased from Sigma.
The D2II anti-extracellular domain of APLP2 was a gift from Drs. Gopal Thinakaran and Sangram S. Sisodia (Dept. of Pharmacological and Physiological Sciences, University of Chicago) (68) . Antibodies against extracellular-signal related kinase (ERK) 2 (p42 MAPK) and phosphorylated ERK1/2 (p42/p44 MAPK) were from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture and treatments. A stably SV40-transfected human corneal epithelial (THCE) cell line that continues to grow and exhibit a cobblestone-like appearance was generously provided by Dr. K. Araki-Sasaki (2). THCE cells were grown in a keratinocyte basic medium (KBM) supplemented with growth factors (KGM; BioWhittaker, Walkersville, MD) in a humidified 5% CO 2 incubator at 37°C. Cells were cultured onto plastic dishes precoated with fibronectin collagen coating mix (Biological Research Faculty and Facility, Ijamsville, MD) and grown to 80% confluence in KGM. Before treatment, the KGM was replaced with KBM for 16 h (growth factor starvation overnight). Cells were then incubated in the presence or absence of test substances freshly dissolved in KBM.
Detection of APLP2 shedding by Western blotting. APLP2 shedding was quantitated after PMA (1 M) or EGF (20 ng/ml) stimulation for 16 h. Staurosporine (40 nM), a broadspectrum inhibitor of protein kinases, was applied 4 min before PMA treatment. After various time intervals, conditioned media were collected, cooled to 4°C, and centrifuged to discard debris. The supernatant fluids were concentrated with Nanosep microconcentrators (10-kDa molecular cutoff; Pall Filtron, Northborough, MA) and quantified. Cultured THCE cells were washed with phosphate-buffered saline [PBS; containing (in mM) 137 NaCl, 10.1 Na2HPO4, 1.8 KH 2PO4, and 2.7 KCl at pH 7.2] and lysed in lysis buffer [containing (in mM) 50 Tris at pH 8.0, 150 NaCl, and 5 EDTA; 0.5% Triton X-100; the following protease inhibitors (in g/ml): 50 pepstatin, 50 leupeptin, and 10 aprotinin; and 0.25 mM phenylmethylsulfonyl fluoride]. After centrifugation to remove detergent-insoluble material, the lysate was subjected to protein determination using a micro BCA (bicinchoninic acid) protein assay reagent kit (Pierce, Rockford, IL).
The detergent-soluble protein in cell lysates or the corresponding portion of conditioned medium was adjusted to equal amounts with Laemmli buffer and fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 5-15% gradient minigels (Bio-Rad, Hercules, CA). After electrophoresis, proteins were transferred electrophoretically to a nitrocellulose membrane (Bio-Rad). Equal amounts of protein loading were confirmed by staining the membranes with Ponceau S. The nonspecific binding sites of membranes were blocked with 5% nonfat skim milk in Tris-buffered saline (20 mM Tris ⅐ HCl, pH 7.6, and 150 mM NaCl) containing 0.05% Tween 20 (TBS-T) at room temperature for 1 h and subsequently incubated with primary antibody against D2II (68) diluted in 5% nonfat milk in TBS-T at room temperature for 1 h. After being washed, membranes were incubated with horseradish peroxidaseconjugated goat anti-rabbit antiserum (Bio-Rad) at room temperature for 1 h. Immune complexes were visualized with enhanced chemiluminescence detection reagent (Pierce).
The chemiluminescent images were captured using the Biological Detection System (Pittsburgh, PA) and quantified using NIH Image (version 1.61) software. The relative amount of APLP2 was the sum of all three bands in each lane. To ensure that experimental values were within the linear range of the assay, we analyzed several exposure times. Results were expressed as square pixels that varied between experiments, in part, because of differences in exposure times and treatment parameters. Thus at least three independent experiments were performed for each treatment, and a control was included in each experiment.
Flow cytometric and immunofluorescence microscopic analyses of APLP2 shedding. Flow cytometry and indirect immunofluorescence were used to assess the loss of APLP2 from the plasma membrane. Growth factor-starved THCE cells were incubated with 1 M PMA or 20 ng/ml EGF for 15 min. Cells were fixed with 4% paraformaldehyde freshly dissolved in PBS without permeabilization. Cells were incubated with D2II antibody and then with FITC-conjugated goat anti-rabbit IgG, both at room temperature, for 1 h. Surface fluorescence was analyzed with an Epics XL flow cytometer (Coulter, Miami, FL). Fluorophores were excited at 488 nm, and emission was collected at 530 nm for FITC. The stained cells were also viewed under a Nikon Eclipse E-800 microscope equipped with a Spot digital camera.
Effects of myristoylated pseudosubstrate-derived peptides and MAPK inhibitor on APLP2 shedding. Four N-myristoylated peptides derived from the pseudosubstrate sequences of PKC-␣␤␥ (myr-PKC-␣␤␥; a 9-amino acid peptide common to all three PKC isozymes), PKC-␣ (myr-PKC-␣, a 14-amino acid peptide unique to PKC-␣), PKC-␦ (myr-PKC-␦), and PKC-⑀ (myr-PKC-⑀) were used to study the role of PKC isozymes in PMA-induced APLP2 shedding. To allow intracellular accumulation of the peptides, we preincubated THCE cells with 1 M of each peptide for 60 min, and they continued in culture with PMA for 16 h. APLP2 shedding was measured by Western blotting as discussed.
To determine whether THCE cells are permeable to the different inhibitor peptides, we biotinylated the myristoylated peptides (67) . THCE cells cultured in eight-chamber wells were incubated for 5 or 15 min at 37°C with 5 M of different biotinylated PKC pseudosubstrate peptides. Cells were washed twice with PBS and then fixed with PBS containing 2.5% paraformaldehyde and 0.01% glutaraldehyde for 15 min at room temperature. Fixed cells were permeabilized with 0.3% Triton X-100 in PBS for 10 min and blocked for 10 min at room temperature with PBS containing 1.5% bovine serum albumin (BSA). Cells were then incubated for 1 h at room temperature with FITC-streptavidin and rhodamine-phalloidin in PBS containing 1.5% BSA for 1 h. The slides were mounted with Vectashield mounting medium with DAPI and examined under a Nikon Eclipse E-800 fluorescence microscope equipped with a Spot digital camera.
To assess the role of MAPK, we pretreated THCE cells with 10 M U-0126, a potent and specific inhibitor of the upstream MAPK regulator, MAPK kinase (MEK) 1/2, for 15 min and then treated with PMA or EGF for 10 min. The stimulation was stopped by the addition of 5 vols of ice-cold KBM. The cells were then washed with PBS, collected in lysis buffer, and subjected to Western blotting using a mouse monoclonal antibody against phosphorylated ERK1/2 and a mouse monoclonal antibody against ERK2.
To determine the function of ERK phosphorylation, we carried out PMA or EGF stimulation for 16 h in the presence of U-0126. At the end of incubation, culture media were collected and APLP2 secretion was determined by Western blotting.
Statistical analysis. Statistical parameters were ascertained with the StatView program (Abacus Concepts, Berkeley, CA), and results were expressed as means Ϯ SE. Statistical differences between groups were determined using Student t-test or between multiple groups using ANOVA. Significance was set at P Ͻ 0.05.
RESULTS
PMA-and EGF-induced APLP2 ectodomain shedding.
To study the extracellular cleavage of transmembrane APLP2, we developed an assay that allowed a convenient and quantitative assessment of APLP2 shedding following stimulation (Fig. 1) . The disappearance of cell-associated APLP2 and appearance of secreted APLP2 were assessed by immunoblotting using antibodies against the extracellular domain of APLP2 (Fig. 1A) . In corneal epithelial cell lysate (cell associated), APLP2 appeared as three bands with different mobilities, resulting from differential glycosylation and processing of transmembrane APLP2 (22) . A discrete band at ϳ105 kDa represented molecules without processing, and a discrete ϳ120-kDa band represented glycosylated but not CS-modified APLP2 (22, 68) . The light band of heterogeneous polypeptides with apparent molecular mass of ϳ130-200 kDa was the result of modification of APLP2 core protein with CS glycosaminoglycan chains of various lengths. Similarly, secreted APLP2 appeared in the medium as the three species but was smaller in size because the secreted forms lack transmembrane and cytoplasmic domains. The ϳ130-to 200-kDa CS glycosaminoglycan chain-modified molecules in the medium were the predominant form of secreted APLP2. The detection of secreted APLP2 allowed a quantitative assessment of the transmembrane APLP2 cleavage, which correlated with immunoreactivity of the soluble APLP2 as assessed by Western blotting.
Using this assay, we quantified PMA-and EGFstimulated cleavage of transmembrane APLP2 and ectodomain release (Fig. 1B) by measuring the relative amount of APLP2 in culture medium (the sum of 3 shifted bands). Shedding of APLP2 in PMA-and EGFtreated THCE cells was significantly increased as assessed by Western blotting and image analysis. Treatment with PMA or EGF resulted in a large increase (5-or 3-fold, respectively, P Ͻ 0.01) in secreted APLP2. Concomitant with this increase, a decrease of the cellular transmembrane APLP2 in PMA-or EGF-treated THCE cells was evident compared with control (Fig.  1A) .
A time-course analysis showed that PMA increased soluble APLP2 immunoreactivity in the culture me- dium starting within 15 min (Fig. 2A) , resulting in a significant increase of APLP2 secretion over basal levels in a time-dependent manner (P Ͻ 0.05). The highest level of APLP2 accumulation in the culture medium was observed at 12 h. The effect of PMA was also concentration dependent, with 1 M PMA treatment resulting in a 4.8-fold increase in shedding over the control (Fig. 2B) .
PMA-induced APLP2 accumulation in media was due to ectodomain shedding. The APP family of proteins is known to be distributed in a variety of cells at the cell surface and in intracellular spaces (13, 75) . Staining of THCE cells with anti-D2II antibody directed against the ectodomain of APLP2 revealed two types of staining patterns: bright surface staining in certain cells and punctate staining in all cells. Treatment of THCE cells with PMA resulted in reduction in cell surface immunoreactivity (bright surface staining), probably due to shedding of cell surface APLP2 (Fig. 3A) . However, punctate staining in PMA-treated cells was still observed, but the intensity was lower. Similarly, EGF also induced reduction of APLP2 cell surface staining (data not shown).
Loss of cell surface APLP2 immunoreactivity was also assessed by flow cytometry (Fig. 3B) . After PMA or EGF treatment, the relative cell number at high-intensity fluorescence peak (10 2 to 10 3 ) was decreased, concomitant with an increase in cell number at low-intensity fluorescence peaks, indicating APLP2 cleavage and consequent release upon PMA or EGF stimulation.
Effect of PKC on APLP2 shedding. Staurosporine, a nonselective protein kinase inhibitor for both tyrosine and serine/threonine kinases (20, 47) , was applied to the culture medium before addition of PMA. Staurosporine reduced PMA-induced shedding of APLP2 ectodomain in THCE cells (66% inhibition, P Ͻ 0.05; Fig. 4) , suggesting a possible pathway through a PMAresponsive protein kinase such as PKC in PMA-induced APLP2 shedding.
Effects of N-myristoylated PKC pseudosubstrate peptides on PMA-induced shedding of APLP2.
To characterize which PKC isozyme(s) mediates APLP2 shedding, we used N-myristoylated peptide inhibitors derived from the pseudosubstrate sequences of PKC-␣␤␥, -␣, -␦, and -⑀ and examined their effects on PMAinduced APLP2 shedding in THCE cells. We first determined the permeability of THCE cells to pseudosubstrate-derived peptides. Biotin-conjugated peptides were synthesized and applied to the cultured cells for 5 or 15 min, followed by detection of biotin in cells. As shown in Fig. 5 , within 5 min, biotin staining was found in a region of THCE cells, suggesting that myristoylated peptide inhibitors enter THCE cells within 5 min at a certain region of the cell body; within 15 min, these peptides were evenly distributed in cells (data not shown). A similar biotin staining pattern was observed for all four myr-PKC peptides (Fig. 5 , myr-PKC-␣ and -⑀). These data suggest that the THCE cells are equally permeable to the different myristoylated peptide inhibitors.
PMA-induced shedding was significantly inhibited by the myristoylated peptide corresponding to the pseudosubstrate sequence of PKC-⑀ (myr-PKC-⑀, 37% decrease compared with PMA, P Ͻ 0.05) but was not inhibited by myr-PKC-␣␤␥ and -␣ (Fig. 6) . Together, these data suggest that PKC-⑀ is involved in stimulating APLP2 shedding, whereas PKC-␣, -␤, and -␥ are not. In a different set of experiments, myr-PKC-␦ ei- ther inhibited APLP2 shedding as effectively as myr-PKC-⑀ or did not inhibit it; the reason for this variability is not clear.
Effects of MEK inhibition on PMA-or EGF-stimulated ERK phosphorylation and APLP2
shedding. Several signaling pathways are activated upon growth factor-induced stimulation of tyrosine kinase receptors. The receptor-activated MAPK cascade mediated by Ras, Raf, and MEK has been suggested to mediate ectodomain shedding of several transmembrane proteins (11, 50, 70) . We therefore tested whether PMA-or EGF-induced APLP2 shedding is also mediated through activation of MAPK. Upon MAPK activation, ERK must be phosphorylated by MEK on both a tyrosine and a threonine residue in the TEY motif (1, 44).
Phosphorylated ERK can be detected using antibodies against the phosphorylated TEY consensus sequence. As shown in Fig. 7 , there was basal phosphorylation of MAPK in untreated growth factor-starved THCE cells. Addition of either PMA or EGF to the cells resulted in an increase in ERK phosphorylation (Fig. 7A) . The presence of U-0126 (10 M) significantly blocked PMAor EGF-induced ERK phosphorylation as reflected by a decreased ratio of phosphorylated ERK1/2 to ERK2 immunoreactivity (pERK/ERK ratio; P Ͻ 0.01 and P Ͻ 0.05 for PMA and EGF, respectively). In addition, U-0126 also inhibited basal phosphorylation of ERK in THCE cells (P Ͻ 0.05).
Addition of U-0126 (10 M) also reduced PMA-or EGF-induced soluble APLP2 to a level similar to or slightly below the basal level ( Fig. 8, P Ͻ 0.05) , suggesting that both PMA-and EGF-induced cleavage of transmembrane APLP2 are due to activation of the MAPK pathway. A similar effect was also observed with PD-98059, another specific inhibitor of MEK (data not shown). Inhibition of the MAPK pathway also significantly affected the basal level of APLP2 cleavage in the absence of exogenous stimulation. Together, these results show that MAPK phosphorylation is related to APLP2 accumulation in the cultured medium of control, PMA-or EGF-treated THCE cells.
DISCUSSION
We have studied the physiological signaling mechanisms that lead to ectodomain shedding of APLP2, a member of the APP family of proteins that is upregulated in the healing corneal epithelium. Several important observations have emerged from our studies. First, activation of PKC with PMA and EGF stimulate ectodomain shedding of APLP2. Second, PKC-⑀, and probably PKC-␦, may be responsible for PMA-induced APLP2 shedding. Third, PMA-induced cleavage of APLP2 occurs through MAPK activation. Finally, activation of the MAPK signaling pathway accounts for PKC-and EGF-induced, as well as the basal level of, APLP2 shedding.
Electrophoretic migration of APLP2 demonstrates that APLP2 recovered from the conditioned medium corresponds to the ectodomain, which lacks the cytoplasmic and transmembrane domains. In THCE cells, the APLP2 ectodomain is shed from cultured cells at a basal rate, but this shedding is markedly enhanced by activating PKC with PMA or by stimulation with EGF, a mitogenic growth factor that has been implicated in regulation of corneal wound healing (76) . Thus we have concluded that APLP2 belongs to the class of transmembrane proteins that undergo proteolytic cleavage and release of their ectodomains into the extracellular milieu and that this ectodomain shedding is regulated by physiological effectors.
In a recent study, we showed PMA-induced translocation of four PKC isozymes, PKC-␣, -␤I, -␦, and -⑀, in THCE cells (Xu, Dartt, and Yu, unpublished observations). One or more of these isozymes is likely to be involved in PMA-induced APLP2 shedding. Although there has been considerable interest in the potential role of PKC isozymes in the process of ectodomain shedding, isolating the role of the individual isozymes has been proven to be complex because of overlapping sensitivity to activators and inhibitors. In this study, we used myristoylated peptides derived from PKC isozyme pseudosubstrate sequences as isozyme-specific inhibitors (78) . Myristoylation of kinase pseudosubstrate peptides enhances their ability to cross intact plasma membranes and thus inhibit intracellular protein kinases. Cell permeability and isozyme selectivity of the myristoylated peptides have been described in detail previously (61, 77, 78) . In line with these previous studies, we showed that these myristoylated pseudosubstrate peptides are readily transported into cultured corneal epithelial cells within 5 min of incubation (Fig. 5) and that the myristoylated peptides do not selectively inhibit translocation of their cognate PKC isoforms in THCE cells (data not shown). This approach is becoming increasingly common in identifying the cellular role(s) of particular protein kinases (19, 32, 64, 67, 78) . We showed that myr-PKC-⑀ inhibitor significantly blocked PMA-induced shedding of APLP2 in THCE cells, whereas myr-PKC-␣␤␥ and -␣ had no apparent effects, suggesting that PKC-⑀ is utilized in PMA-induced shedding of APLP2. Izumi et al. (27) showed that PKC-␦ is involved in PMA-induced ectodomain shedding of HB-EGF. We also observed in some experiments that PKC-␦ myristoylated pseudosubstrate peptide was as effective as PKC-⑀ pseudosubstrate. However, sometimes PKC-␦ pseudosubstrate exhibited no effect on PMA-induced ectodomain shedding. The reason for the inconsistent results of PKC-␦ pseudosubstrate is not clear but may be related to the complicated mechanisms of action of these pseudosubstrates, which currently are not fully understood (23, 78) . Consistent with our results, PKC-⑀ was implicated in PMA-induced APP secretion in APP-transfected Chinese hamster ovary (CHO) cells (28) . The same study also suggested a role for PKC-␣ in APP secretion in human Ntera 2 neurons and in CHO cells. Several other studies also reported the involvement of PKC-␣ in regulation of APP secretions in fibroblast cells (4, 28, 30, 60) . It is not clear whether the difference in PKC-␣ involvement between previously reported studies and our current studies is due to the different cell types used or to the subtle differences between APLP2 and APP secretion (28) . A comparative study of PMA-induced secretion of APLP2 with APP in epithelial and in neuronal cells is needed to clarify this issue.
Consistent with the previous studies of APP secretion mediated by ␣-secretase (12, 36) , our results assessing ERK phosphorylation and using the highly specific MEK inhibitor U-0126 suggest a key role for MAPK signaling cascade in regulating APLP2 shedding. Inhibition of this pathway completely blocked EGF-induced ectodomain shedding and partially de- creased the basal level of ectodomain cleavage in cultured THCE cells. Inhibition of basal shedding of APLP2 by U-0126 is different from that of TGF-␣, which is mediated through p38 MAPK signaling pathway (15) , suggesting that certain differences exist for the regulation of transmembrane protein shedding between different cell types or different shed proteins. We also observed that ERK is phosphorylated at a basal level without growth factor stimulation, and this basal phosphorylation may be responsible for the basal level of APLP2 shedding. It is not clear whether the basal level of APLP2 shedding is a result of cell culture conditions and SV40 transfection or a reflection of a constitutive level of shedding under normal physiological conditions in vivo.
In THCE cells, the induction of MAPK signaling accounted for the activation of ectodomain shedding by PMA, a potent activator of PKC. Inhibition of PMAinduced shedding by U-0126 suggests that APLP2 shedding is not a direct consequence of PKC activity but, rather, results from PKC-induced activation of MAPK. The fact that PKC activation induces MAPK signaling suggests that in corneal epithelial cells, PKC may play a role in the activation of MAPK signaling by growth factor receptors. However, our observations that EGF stimulation does not induce translocation of PKC isozymes (Xu, Dartt, and Yu, unpublished observations) and that the specific PKC inhibitors calphostin C and chelerythrine chloride fail to block EGFinduced APLP2 secretion (data not shown) suggest that EGF stimulation is PKC independent. To date, the natural stimuli that induce PKC activation that in turn mediates APLP2 secretion in corneal epithelial cells is not known.
Because MAPK signaling is induced by growth factors, various tyrosine kinases, and oncogenes (9, 50, 70) , a large variety of stimuli and changes in the cellular environment may lead to ectodomain shedding of APLP2 and other transmembrane proteins through the same signaling pathways (15) . Our data demonstrate that EGF is one of such growth factors that activate MAPK and promote APLP2 secretion. NGF is another factor known to stimulate APP secretion (12, 36, 38), while insulin induces APP secretion by MAPKindependent pathways. The best-characterized means of stimulating the MAPK pathway is by activation of receptor tyrosine kinases (8) . Our data indicated that the "direct route" of ERK activation by receptor tyrosine kinases is necessary and sufficient for growth factor, such as EGF, stimulation of APLP2 secretion in epithelial cells.
The mechanism by which the MAPK pathway regulates APLP2 shedding is unknown. It is possible that upregulation of APLP2 by EGF and/or PMA treatment contributes to the increased accumulation of APLP2 in culture medium. We observed depletion of cell surface APLP2 within 15 min (Fig. 3) of PMA stimulation. We also reported that complete PMA-induced translocation of PKC isozymes occurs within 10 min (Xu, Dartt, and Yu, unpublished observations). The time course of APLP2 shedding in response to PMA stimulation suggests that activation of MAPK induces APLP2 shedding, at least in part, by increasing secretase activity. This increased cleavage activity may also shed newly inserted APLP2 from cell surface, thus reducing or preventing possible internalization of the molecules in activated cells. These suggestions are consistent with a recent observation that the majority of secreted APP originates from the intracellular compartment (28) . As expected, the enzyme response for APLP2 shedding in corneal epithelial cells is sensitive to metalloproteinase inhibitor GM-6001 (Xu, Dartt, and Yu, unpublished observations). Two ADAM family members, TNF-␣-converting enzyme (TACE) (6) and ADAM-10 (31), have been shown to contribute to the cleavage of APP. Recently, using an APP mutant construct specifically targeted to the trans-Golgi network (TGN), Skovronsky et al. (57) demonstrated that regulated ␣-secretase (TACE/ADAM-10) APP cleavage occurs in the TGN. Although our study cannot distinguish intracellular or cell surface cleavage, the facts that cell surface staining of APLP2 is diminished upon both PMA and EGF stimulation within 15 min and that the time required for one-half of the total APLP2 to be secreted under normal conditions is 2 h (34) imply that at least some activation of APLP2 cleavage enzyme occurs at the cell surface.
The facts that EGF activates ectodomain shedding of APLP2 in vitro and that secreted APP and APLP2 are accumulated in the traumatic brain and wounded corneas, respectively, suggest physiological relevance for the release of APP family from cells. Recently, the EGF receptor was found to be activated in wounded corneal epithelia, a step that appears to be necessary for epithelial cell migration and wound closure (76) . This EGF receptor activation is consistent with increased expression and secretion of APLP2 in migratory epithelial cells in vivo (22) . Our previous studies revealed that the majority of APLP2 molecules in the corneal epithelium contain a KPI domain and are posttranslationally modified by the addition of CS (22) . The KPI domain is known to inhibit certain serine proteases including plasmin, which is involved in corneal wound healing (24, 71) . Thus release of APLP2 derivatives and their incorporation into ECM may inhibit matrixassociated serine proteinase activity in wounded corneas. Hence, wound-induced shedding may provide a mechanism to balance proteinase activity during ECM remodeling. CS proteoglycans in the ECM of the central nervous system, including neurocan and phosphocan, are believed to modulate cell adhesion, axonal growth, and guidance during neural development (5, 21) . Our observation that CS-modified APLP2 promotes cell adhesion and migration in vitro and is concentrated in front of the migratory epithelial sheet in vivo suggests a similar role for the protein in epithelial wound healing of the cornea. As such, regulation of APLP2 ectodomain shedding as demonstrated here may be of physiological significance for the protein to function in epithelial cell migration and wound healing. Further studies are needed to clarify the functional role of the ectodomain shedding process and of shed molecules of the APP-like proteins in regulating corneal epithelial wound healing or other biological processes.
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